BioCentury
ARTICLE | Company News

Biota Pharmaceuticals, U.S. Department of Health and Human Services infectious news

May 12, 2014 7:00 AM UTC

Biota said HHS's Office of the Assistant Secretary for Preparedness and Response (ASPR) and Biomedical Advanced Research and Development Authority (BARDA) terminated a 2011 contract worth up to $231 million to develop the company's laninamivir octanoate. Biota said HHS did not provide a reason for the contract termination. In April, Biota received a stop-work order for the influenza candidate (see BioCentury, May 5). ...